Illinois Expands Newborn Screening to Include Rare Genetic Disorders, Paving Way for Early Treatment and Improved Outcomes

In Illinois, the fight against rare genetic disorders is gaining ground, thanks to the concerted efforts of families and the medical community. Starting soon, all newborns in the state will undergo screening for GAMT, a rare creatine deficiency disorder, as well as for SMA, spinal muscular atrophy—a genetic, progressive neuromuscular disorder. This push for early detection stands to change the trajectory of countless young lives.

Beth and Jerry Robinson of Oswego learned about GAMT the hard way, after their children Benny and Celia were diagnosed with the condition. According to NBC Chicago, "Celia's diagnosis at an earlier age made a huge impact on her quality of life," illustrating the significance of early intervention. The siblings' contrasting experiences underscore the need for early screening—a narrative that contributed to the advocacy that ultimately led to this policy change.

The Illinois initiative to include SMA in new screenings is also a major leap forward for early diagnosis. Dr. Mary Schroth, Chief Medical Officer for Elk Grove Village-based Cure SMA, emphasized the urgency, telling WTTW News, "Once these infants start to lose function, demonstrate signs of weakness/disease, that loss is irreversible." Immediate treatment following a positive screening for SMA is crucial, and Illinois' readiness to start this screening notwithstanding the concurrent public health challenges of COVID-19 is both commendable and crucial.

Add to these disorders, Illinois' newborn screening program already covers conditions like cystic fibrosis, Gaucher disease, and sickle cell disease. Each of these efforts marks a significant step in preventative care, potentially sparing families from the harrowing consequences of late diagnoses. As for SMA, with Illinois now joining the frontline, half of the states in the U.S. are testing for the disorder, an emergency that requires decisive action once diagnosed, given the availability of life-changing treatments.

With similar dedication to GAMT, thanks to advocates like the Robinsons, Illinois is setting a precedent for genetic screening. Testing for creatine deficiency disorders was approved in January, and as of now, newborns will soon be able to receive a diagnosis for this condition in their first weeks of life. "Adding GAMT or creatine disorders will be a significant milestone because you can diagnose them first week, second week of life," said Dr. Carlos Prada of the Division of Genetics, Genomics & Metabolism at Lurie Children’s Hospital, as recounted by NBC Chicago. As health advancements like these are embraced, parents can look forward to healthier starts for their new babies.